Skip to main content

Search articles in News

Found 2,761 articles

  • Cumulus Oncology Appoints Catherine Lewis La Torre

    Cumulus Oncology Appoints Catherine Lewis La Torre to its Board of Directors

    • 11 Jun 2024
    • Editor

    Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to its Board of Directors.

  • IQVIA Institute: Innovative Therapies and Strong P

    IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses

    • 11 Jun 2024
    • Editor

    As cancer incidence continues to rise, it’s being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report from the IQVIA Institute for Human Data Science titled, “Global Oncology Trends 2024: Outlook to 2028.”

  • Tagrisso granted Priority Review in the US for pat

    Tagrisso granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

    • 10 Jun 2024
    • Editor

    AstraZeneca’s supplemental New Drug Application (sNDA) for has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT).

  • European Commission approves Roche’s Alecensa as t

    European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

    • 10 Jun 2024
    • Editor

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Alecensa® (alectinib) monotherapy, as adjuvant treatment following tumour resection for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at high risk of recurrence (Stage IB [≥4 cm]–IIIA NSCLC [7ᵗʰ edition UICC/AJCC]).

  • AbbVie Launches First-of-its-Kind Contest to Empow

    AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers

    • 7 Jun 2024
    • Editor

    AbbVie (NYSE: ABBV) today launched the AbbVie Migraine Career Catalyst AwardTM, a first-of-its-kind contest designed to support the career, workplace, and professional development aspirations of people living with migraine. With more than 113 million workdays lost in the U.S. each year to the disease and its symptoms, migraine can have a major impact in the workplace.

  • ABBOTT RECEIVES CE MARK FOR AVEIR™ DR, THE WORLD'S

    ABBOTT RECEIVES CE MARK FOR AVEIR™ DR, THE WORLD'S FIRST DUAL CHAMBER LEADLESS PACEMAKER SYSTEM

    • 7 Jun 2024
    • Editor

    Abbott today announced it has received CE Mark in Europe for the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms. Approximately 49 million people are living with cardiovascular disease in the European Union, and it is estimated that 14.4 million people 65 and older will have atrial fibrillation by 2060.

  • Moderna's Investigational Therapeutic for Methylma

    Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

    • 7 Jun 2024
    • Editor

    Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia (MMA) due to methylmalonic-CoA mutase (MUT) deficiency.

  • Top Companies Hiring in June

    Top Companies Hiring in June

    • 6 Jun 2024
    • Nola Cadman

    Here's a list of the top pharma and life science companies hiring in June on PharmiWeb.jobs

  • Danaher Appoints Martin Stumpe to New Role of Chie

    Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer

    • 6 Jun 2024
    • Editor

    Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role.

  • AbbVie Advances Oncology Pipeline With Start of Mu

    AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

    • 6 Jun 2024
    • Editor

    AbbVie (NYSE: ABBV) today announced that the first patient has been treated with investigational ABBV-383 in the CERVINO Phase 3 study.

  • Gilead’s Seladelpar Demonstrated a Sustained and C

    Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

    • 6 Jun 2024
    • Editor

    Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease.

  • GeneType and Stayhealthy Announce Landmark Distrib

    GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test

    • 6 Jun 2024
    • Editor

    Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are excited to announce a major distribution agreement.

  • From Clinical Trials to Patient Education: AI’s Tr

    From Clinical Trials to Patient Education: AI’s Transformative Role in Medical Writing

    • 5 Jun 2024
    • Lucy Walters

    The integration of Artificial Intelligence (AI) into various sectors has been nothing short of revolutionary, and the field of medical writing is no exception. From the intricate documentation of clinical trials to the nuanced task of patient education, AI technologies are transforming the landscape of medical communication.

  • Gilead Sciences Advances Enrollment in Collaborati

    Gilead Sciences Advances Enrollment in Collaborative Studies to Assess Twice-Yearly HIV Prevention Option for Both Cisgender Women in the U.S. and People Who Inject Drugs in the U.S.

    • 5 Jun 2024
    • Editor

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company is advancing enrollment in two groundbreaking collaborative studies to evaluate the tolerability of an investigational long-acting HIV prevention option in groups of people in the United States who are disproportionately affected by HIV but who are often underrepresented in HIV clinical trials.

  • Melissa Seymour to join Lilly as executive vice pr

    Melissa Seymour to join Lilly as executive vice president of Global Quality

    • 5 Jun 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024. Seymour currently serves as the chief quality officer for Bristol Myers Squibb and succeeds Johna Norton, whose retirement after 34 years of service was announced earlier this year.

  • Acquisition of Fusion completed

    Acquisition of Fusion completed

    • 5 Jun 2024
    • Editor

    AstraZeneca today announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

  • Michael McSorley appointed as new Managing Directo

    Michael McSorley appointed as new Managing Director of Origin

    • 5 Jun 2024
    • Editor

    Global pharmaceutical solutions provider, Origin, has today appointed Michael McSorley as new Managing Director.

  • Top Recruiters Hiring in June

    • 4 Jun 2024

    Here are the top Pharma and Life Science recruitment organisations advertising in June 2024 on PharmiWeb.jobs

  • A Recruiter’s Guide to Hiring a Medical Writer

    A Recruiter’s Guide to Hiring a Medical Writer

    • 4 Jun 2024
    • Lucy Walters

    In this recruiter guide, we explore the essential considerations for you to keep in mind when hiring a Medical Writer. From understanding the unique demands of the role to identifying key competencies and conducting effective interviews, this guide will help you to focus your candidate search and engage your target audience of talent.

  • Labcorp Announces New Strategic Service Offerings

    Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio

    • 4 Jun 2024
    • Editor

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced new strategic service offerings within its precision oncology portfolio.